Alecensa (Alectinib)
alectinib 150 mg capsule, 4 x 56 · ORAL · PBS code 11226W
AUTHORITY_REQUIREDWhat it costs
AU$6320.43 PBS-determined price per 224 units
Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.
- • First listed on the PBS: 2018-01-01.
- • Repeats: 3.
- • PBS program: GE.
Eligibility criteria for subsidised access
The following is the government's own wording from the PBS Schedule, shown unchanged.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer (NSCLC)
Initial treatment
Patient must not have previously received PBS-subsidised treatment with alectinib as adjuvant therapy in resected non-small cell lung cancer; AND
The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this condition; AND
The condition must be non-squamous type non-small cell lung cancer (NSCLC) or not otherwise specified type NSCLC; AND
Patient must have a WHO performance status of 2 or less; AND
Patient must have evidence of an anaplastic lymphoma kinase (ALK) gene rearrangement in tumour material, defined as either: (i) 15% (or greater) positive cells by fluorescence in situ hybridisation (FISH) testing, (ii) positive next generation sequencing (NGS) testing; AND
Must be treated by a medical practitioner.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer (NSCLC)
Continuing treatment
The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this condition; AND
Patient must have previously received PBS-subsidised treatment with this drug for this indication (i.e. for stage IIIB/IV NSCLC); AND
Patient must not develop disease progression while receiving PBS-subsidised treatment with this drug for this condition; AND
Must be treated by a medical practitioner; or
Must be treated by a nurse practitioner where both of the following are occurring: (i) patient care is being shared with a medical practitioner, (ii) the prescription continues existing therapy with this medicine.
Sponsor: Roche Products Pty Ltd ABN 70 000 132 865
Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.